Across TCGA pan-cancer cohorts, ASB8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ASB8 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ASB8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASB8 expression acts as an unfavorable survival marker.
KIRP and PRAD are the cancer types where ASB8 Mutation most reproducibly stratifies survival.